Promising New Molecular Targeted Therapies in Head and Neck Cancer

Cancer statistics, 2012

2012 • 10,655 citations

Angiogenesis in cancer, vascular, rheumatoid and other disease

1995 • 7,717 citations

Cancer Statistics, 2007

2007 • 7,372 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2002 • 5,914 citations

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

2010 • 5,874 citations

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

2006 • 4,800 citations

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1995 • 3,977 citations

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 • 3,395 citations

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

2008 • 2,660 citations

EGFR and cancer prognosis

2001 • 2,068 citations

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

2009 • 1,892 citations

Insulin-like growth factors and neoplasia

2004 • 1,452 citations

Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains

2002 • 1,158 citations

Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor

2002 • 972 citations

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 • 937 citations

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

2005 • 879 citations

Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

2004 • 813 citations

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

2003 • 803 citations

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

2000 • 748 citations

Trends in head and neck cancer incidence in relation to smoking prevalence

2007 • 747 citations

Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

2003 • 616 citations

Structure and function of the type 1 insulin-like growth factor receptor

2000 • 602 citations

The ErbB receptors and their role in cancer progression

2003 • 590 citations

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity

2004 • 544 citations

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

2000 • 498 citations

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

2005 • 483 citations

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

2001 • 452 citations

Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies

1984 • 443 citations

Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?

2002 • 436 citations

Predictors of Competing Mortality in Advanced Head and Neck Cancer

2009 • 432 citations

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

1999 • 419 citations

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

2005 • 395 citations

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

2009 • 373 citations

Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm

2006 • 300 citations

Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic

2006 • 291 citations

Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients

2004 • 288 citations

EGFR Targeting of Solid Tumors

2007 • 271 citations

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

2009 • 267 citations

The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer

2009 • 264 citations

Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

2006 • 262 citations

Head and neck cancer: past, present and future

2006 • 252 citations

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

2007 • 251 citations

Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

2005 • 249 citations

Role of insulin-like growth factor 1 receptor signalling in cancer

2005 • 241 citations

Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma

2007 • 239 citations

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

2011 • 238 citations

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

2005 • 235 citations

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

2009 • 229 citations

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

2004 • 218 citations

Biology of Interactions: Antiepidermal Growth Factor Receptor Agents

2007 • 214 citations

The Expanding Role of Systemic Therapy in Head and Neck Cancer

2004 • 213 citations

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

2001 • 202 citations

Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial

2005 • 194 citations

Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformation

1991 • 193 citations

Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

2001 • 192 citations

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

2006 • 190 citations

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

2010 • 185 citations

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

2011 • 184 citations

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

2009 • 170 citations

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

2010 • 162 citations

The p53 network in head and neck cancer

2003 • 158 citations

Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

2007 • 151 citations

Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

2007 • 143 citations

The ErbB receptor tyrosine family as signal integrators.

2001 • 139 citations

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

2011 • 115 citations

Cetuximab

2007 • 113 citations

Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

2010 • 110 citations

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

2011 • 108 citations

End points for new agents in induction chemotherapy for locally advanced head and neck cancers

2002 • 105 citations

Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib

2007 • 98 citations

Computational Identification of Inhibitors of Protein-Protein Interactions

2006 • 84 citations

A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)

2006 • 83 citations

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study

2009 • 82 citations

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

2009 • 80 citations

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

2012 • 79 citations

The role of ubiquitylation in signaling by growth factors: implications to cancer

2002 • 75 citations

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

2006 • 74 citations

The IGF-1 receptor and its contributions to metastatic tumor growth—novel approaches to the inhibition of IGF-1R function

2005 • 73 citations

Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.

2003 • 73 citations

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

2007 • 65 citations

Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for Patients With Locally Advanced Squamous Cell Head and Neck Cancer

2007 • 65 citations

Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

2004 • 64 citations

EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer

2006 • 63 citations

Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2

2004 • 62 citations

Molecular Design and Clinical Development of VEGFR Kinase Inhibitors

2007 • 59 citations

Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer

2006 • 59 citations

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

2012 • 55 citations

Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer

2007 • 51 citations

Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca)

2005 • 47 citations

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

2005 • 46 citations

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer

2006 • 45 citations

Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck

2005 • 44 citations

The Roles of JNK1 and Stat3 in the Response of Head and Neck Cancer Cell Lines to Combined Treatment with All trans‐retinoic Acid and 5‐Fluorouracil

2002 • 40 citations

Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303)

2007 • 39 citations

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

2010 • 37 citations

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

2005 • 35 citations

A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG)

2009 • 35 citations

A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

2012 • 33 citations

Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN)

2006 • 32 citations

A phase II trial of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial

2006 • 31 citations

Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).

2010 • 27 citations

Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.

2012 • 24 citations

An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM)

2009 • 24 citations

Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

2012 • 23 citations

Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis

2007 • 21 citations

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study.

2011 • 21 citations

Targeting Angiogenesis in Head and Neck Cancer

2007 • 20 citations

Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study

2007 • 19 citations

Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)

2007 • 17 citations

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN)

2007 • 17 citations

pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)

2007 • 13 citations

Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results.

2011 • 10 citations

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

2011 • 10 citations

Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.

2012 • 7 citations

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

2011 • 7 citations

A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

2007 • 4 citations

Malignancies of the head and neck: the role for molecular targeted agents

2007 • 4 citations

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

2004 • 3 citations